- 近視抑制に働く分子メカニズムを世界初で解明 バイオレット光(ライト)は非視覚光受容体OPN5を介して近視進行抑制する －光受容タンパク質OPN5の機能解明と近視治療ターゲットとしての期待－
- バイオレット光の近視抑制効果を確認 近視の進行を抑える医療機器の探索的治験で大きなマイルストン
- バイオレットライト透過眼鏡の装用で強度近視が改善(症例報告) ─保存的治療で強度近視が改善・眼軸長が短縮した症例―
Case Report of Axial Length Shortening in a High Myopic Child After Wearing Violet Light-Transmitting Eyeglasses
- 近視の進行を抑える医療機器の開発に大きな一歩 探索的臨床試験で安全性を確認
A major step in the development of a medical device for the suppression of myopia progression Safety was confirmed in the exploratory clinical trial
- 研究員募集のお知らせ
研究員募集のお知らせ
- 窪田製薬ホールディングス株式会社が発表した「クボタメガネ」について
Our comments on the press release for the “Kubota Glasses” Developed by Kubota Pharmaceutical Holdings Co., Ltd.
- 2020年6月8日−12日開催の「2020 BIO International Convention Digital」に参加します。
We will join 2020 BIO International Convention Digital.
- 2019年3月19日（木）アスキー主催のJAPAN INNOVATION DAY 2020への出展します！
We have a booth at "JAPAN INNOVATION DAY 2020 by ASCII STARTUP!” on March 19!
- 特許庁の2019年度「知財アクセラレーションプログラムIPAS2019」に選ばれました！
We were selected as a participant in the "IP Acceleration program for Startups (IPAS)" of Japan Patent Office for this fiscal year.
- 湖北省・国際イノベーションコンファレンス ビジネスコンテストで「近視進行抑制の研究と事業展開」にて3位を受賞しました。
We won the third prize in the "2019 International Science and Technology Innovation and Entrepreneurship Competition" held in Wuhan, Hubei Province, China. The participants were startups from the US, UK, Japan, France, Canada and Singapore, and presented their new technologies and business models.
- NEDOの2019年度「研究開発型ベンチャー支援事業／シード期の研究開発型ベンチャーに対する事業化支援」の事業者に選ばれました！
We were selected as a recipient of a NEDO grant for Seed-stage Technology-based Startups (STS) for this fiscal year.
- NHK「近視クライシス」に出演
“Myopia Crisis” featured on NHK Broadcasting
- 中小機構の令和元年度「戦略的知財活用海外展開補助金」を獲得しました！
We were selected as a recipient of the "Strategic IP Overseas Expansion Grant" of Organization for Small & Medium Enterprises and Regional Innovation, Japan for this fiscal year.
- 現在、6～12歳（小学校1年生～6年生）の方で、近視と診断された方を対象としたメガネ型医療機器の治験を実施しています。※治験参加者の募集は終了いたしました。
We are conducting a clinical trial with our eyeglasses-type medical device for myopic grade school children aged from 6 to 12.
- 慶大眼科より日本の小中学生の近視増加に関する論文を発表しました。
The paper on current prevalence on myopia was published on JAMA OPHTHALMOLOGY.
- 慶大眼科よりクロセチンが児童の近視進行を抑制することに関する論文を発表しました。
The paper on the effects of crocetin on myopia suppression in children was published on Journal of Clinical Medicine.
- KEIO RESEACH HIGHLIGHTSで近視研究が紹介されました。
Prof. Tsubota’s was interviewed by KEIO RESEACH HIGHLIGHTS.
- 近視進行抑制に効果のあるメガネを開発し、現在治験を実施中。(特許第6085722号；特許第6175210号)
Myopia Suppression Glasses are under clinical trial (patents pending: JP6085722、WO/2015/186723；JP6175210、WO/2017/94886)
- 坪田一男が代表取締役に就任しました。
Dr Kazuo Tsubota was appotined as CEO.
- 近視とクロセチンに関する論文を発表しました。
The paper on crocetin and myopia was published.
- Case Report of Axial Length Shortening in a High Myopic Child After Wearing Violet Light-Transmitting Eyeglasses
- A major step in the development of a medical device for the suppression of myopia progression Safety was confirmed in the exploratory clinical trial
- 研究員募集のお知らせ
- Our comments on the press release for the “Kubota Glasses” Developed by Kubota Pharmaceutical Holdings Co., Ltd.
- We will join 2020 BIO International Convention Digital.
- We have a booth at "JAPAN INNOVATION DAY 2020 by ASCII STARTUP!” on March 19!
- We were selected as a participant in the "IP Acceleration program for Startups (IPAS)" of Japan Patent Office for this fiscal year.
- We won the third prize in the "2019 International Science and Technology Innovation and Entrepreneurship Competition" held in Wuhan, Hubei Province, China. The participants were startups from the US, UK, Japan, France, Canada and Singapore, and presented their new technologies and business models.
- We were selected as a recipient of a NEDO grant for Seed-stage Technology-based Startups (STS) for this fiscal year.
- “Myopia Crisis” featured on NHK Broadcasting
- We were selected as a recipient of the "Strategic IP Overseas Expansion Grant" of Organization for Small & Medium Enterprises and Regional Innovation, Japan for this fiscal year.
- We are conducting a clinical trial with our eyeglasses-type medical device for myopic grade school children aged from 6 to 12.
- The paper on current prevalence on myopia was published on JAMA OPHTHALMOLOGY.
- The paper on the effects of crocetin on myopia suppression in children was published on Journal of Clinical Medicine.
- Prof. Tsubota’s was interviewed by KEIO RESEACH HIGHLIGHTS.
- Myopia Suppression Glasses are under clinical trial (patents pending: JP6085722、WO/2015/186723；JP6175210、WO/2017/94886)
- Dr Kazuo Tsubota was appotined as CEO.
- The paper on crocetin and myopia was published.
